Methods for selecting and detecting binding peptides

Through the method of binding of puromycin-DNA linker to fluorescent labels, combined with FACS and flow cytometry, the problem of difficult to select cells to express targets and distinguish specific binding in the prior art is solved, and the accuracy of target-specific peptides is achieved Enrichment and functional selection.

CN113661240BActive Publication Date: 2024-11-05ELI LILLY & CO
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080026300.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-02
Filing Date
2020-03-31
Publication Date
2024-11-05
Estimated Expiration
2040-03-31

AI Technical Summary

Technical Problem

Existing mRNA display technology is difficult to select targets for cell expression, and traditional methods are difficult to distinguish specific and nonspecific binding compounds when measured by qPCR, resulting in inaccurate selection efficiency.

Method used

The enrichment of target-specific peptides was monitored by FACS and flow cytometry using a puromycin-DNA linker to bind to fluorescent labels, binding tags such as FLAGTM tags to achieve specific selection and identification, and the selection conditions were adjusted based on real-time data.

Benefits of technology

Accurate enrichment and functional selection of target-specific peptides is achieved, reducing the selection of nonspecific binding agents, improving selection efficiency, and allowing the identification of internalizable peptides in cells.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GDA0005035921640000081
    Figure GDA0005035921640000081
  • Figure GDA0005035921640000091
    Figure GDA0005035921640000091
Patent Text Reader

Abstract

The present invention provides methods for selecting, detecting and / or enriching peptides that bind to a target.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of mRNA display technology. More specifically, the present invention relates to a method for selecting, detecting and / or enriching peptides expressed by cells or soluble peptides, and peptides with desired functional properties. Background Art

[0002] Messenger RNA (mRNA) display is a selection technology for soluble peptides and soluble proteins. (Szostak R. et al., RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl. Acad. Sci. 94, 12297-12302 (1997)). Using messenger RNA display can construct a highly diverse peptide library, which can include natural amino acids and unnatural amino acids. Unnatural amino acids can be incorporated by different methods, including suppressing amber codons and using modified tRNA (chemical conjugates of unnatural amino acids and tRNA) or using highly flexible tRNA aminoacylases made from artificial ribozymes (called flexizymes) (Niwa N. et al., Aflexizyme that selectively charges amino acids activated by a water-friendlyleaving group. Bioorganic & Med. Chem. Letters 19 (14), 3892-3894 (2009)).

[0003] Methods for selecting peptides using mRNA display traditionally involve transcribing mRNA from a library of DNA variants and annealing these mRNA variants to a short DNA linker that is conjugated to puromycin at its 3' end (Ishizawa T. et al., TRAP Display: A High-Speed ​​Selection Method for the Generation of Functional Polypeptides. J. Am. Chem. Soc. 135 (14), 5433-5440 (2013)). This will generate an mRNA: DNA linker-puromycin library. By adding bacterial or rabbit reticulocyte lysate or Pure Start translation.

[0004] During translation, ribosomes move along a single mRNA and translate the genetic information stored in the mRNA into a peptide sequence. When the ribosomes encounter the TAG stop codon designed at the end of the peptide sequence, they stall in the absence of release factor 1, allowing puromycin to enter ribosomal site A. As a result, puromycin forms a covalent bond between the growing polypeptide chain and the mRNA. Translation stops, and the mRNA hybridized with the DNA linker fused to puromycin is now connected to the peptide. The mRNA is then reverse transcribed into cDNA to allow PCR amplification and the generation of stable DNA: RNA duplexes with reduced nonspecific binding during the selection process. The library is selected for the target of interest, nonspecific peptides are washed away, and the binder is eluted. The selection efficiency is monitored by quantitative PCR (qPCR). Next generation sequencing is used to determine the peptide sequence enriched after multiple rounds of sequencing.

[0005] Although specific strong binders for soluble peptides have been produced by mRNA library selection, mRNA display is not suitable for the selection of targets expressed by cells. Therefore, there is still a need for methods for selecting targets expressed by cells such as proteins or protein analogs. In addition, most previous methods use qPCR to determine the ratio (percent recovery rate) of output and input molecules to determine efficiency. However, the peptide selected includes both specific binders and non-specific binders. Therefore, it is necessary to select only the method for specific binders. SUMMARY OF THE INVENTION

[0007] Therefore, the present invention provides the method for selecting mRNA display library for cell-expressed and soluble peptides or peptide analogs. The present invention also provides a means of monitoring the enrichment of target-specific peptides in each round of selection in a quantitative manner, which will be a more accurate measurement method for determining efficiency. In addition, the selection conditions of the present invention can be modified based on the data obtained in real time, to select for soluble and cell-expressed targets. In addition, the present invention allows to be incorporated into FACS to select target-specific peptides for cell-expressed and recombinant proteins, allows to carry out functional selection (selecting peptides with desired functions in cell-based assays), and can identify the peptides internalized in cells.

[0008] Puromycin is attached to a short DNA linker to obtain a puromycin-DNA linker. A fluorophore is then fused to the 5' end of the puromycin-DNA linker, so that the resulting DNA linker is fused to puromycin at its 3' end and to the fluorophore at its 5' end. Therefore, when annealed with the DNA linker, each mRNA-DNA-peptide molecule in the library is automatically labeled with a fluorophore, thereby enabling the integration of FACS and flow cytometry with the mRNA display platform. In a similar approach, a tag (e.g., FLAG TMA tag) is incorporated into the mRNA-DNA-peptide complex so that a fluorescent peptide, antibody or other fluorescent molecule specific to the tag is bound to the mRNA-DNA-peptide molecule, thereby realizing the integration of FACS and flow cytometry.

[0009] This integration of FACS and flow cytometry provides a means to monitor the enrichment of target-specific peptides in a quantitative manner in each round of selection, while previous methods use qPCR to determine the ratio of output to input molecules (percent recovery). The method of the present invention provides an advantage over qPCR percent recovery determination, for which both specific and non-specific binders are selected during each round of selection. Therefore, the use of qPCR percent recovery determination results in the measurement of both specific and non-specific binders in each round of selection. Enrichment and selection by flow cytometry and FACS allows the selection of most specific binders.

[0010] The method of the present invention is also advantageous because selection conditions can be modified based on data obtained in real time. In addition, this method allows the combination of FACS to select target-specific peptides for cell-expressed and recombinant proteins, allowing functional selection and enabling identification of peptides that can be internalized by cells.

[0011] Therefore, the present invention provides a method for detecting or selecting a binding peptide of a target, wherein the method comprises detecting or selecting an mRNA-DNA-peptide complex connected to at least one detectable substance. In one embodiment, the detectable substance is a fluorophore. In a specific embodiment, the fluorophore is an organic dye, a biological fluorophore, or a quantum dot. In a specific embodiment, the detectable substance is Alexa Fluor. In some embodiments, the detectable substance is conjugated to a puromycin linker.

[0012] The present invention also provides a method for detecting or selecting a binding peptide of a target, wherein the method comprises detecting or selecting an mRNA-DNA-peptide complex linked to at least one detectable substance, and wherein the detectable substance is a tag. In one embodiment, the tag comprises a natural or unnatural amino acid. In one embodiment, the tag is a peptide tag. In a specific embodiment, the peptide tag is FLAG TM Tags. In one embodiment, the tags are detected by fluorescent molecules. In a specific embodiment, the tags are detected by fluorescent peptides. In another specific embodiment, the tags are detected by fluorescent antibodies.

[0013] In one embodiment, the method of the present invention comprises a target fixed on a material capable of sorting. In a specific embodiment, the material capable of sorting is a bead. In one embodiment, the target is a peptide, protein, nucleic acid, sugar, lipid, mammalian cell or mammalian cell extract. In a specific embodiment, the target is a peptide or protein.

[0014] In one embodiment, the methods of the invention include a binding peptide comprising at least one unnatural amino acid.

[0015] In another embodiment, the binding peptide of the method of the present invention is detected or selected by a detectable substance. In some such embodiments, the binding peptide is detected or selected by flow cytometry or FACS. In other such embodiments, the binding peptide is detected or selected by ELISA, spectrophotometry, fluorescence spectroscopy or microscopy. In a preferred embodiment, the binding peptide is detected by flow cytometry. In another preferred embodiment, the binding peptide is selected by FACS. In one embodiment, detect and select the binding peptide. In some such embodiments, the binding peptide is detected by flow cytometry and the binding peptide is selected by FACS.

[0016] In one embodiment, the method of the present invention includes incorporating at least one detectable substance into an mRNA library to produce an mRNA-detectable substance complex. In another embodiment, the method of the present invention includes translating an mRNA-detectable substance complex to produce an mRNA-peptide-detectable substance complex. In a further embodiment, the method of the present invention includes reverse transcribing an mRNA-peptide-detectable substance complex to obtain an mRNA-DNA-peptide-detectable substance complex. In a specific embodiment, the method of the present invention includes incorporating at least one detectable substance into an mRNA library to produce an mRNA-detectable substance complex, translating an mRNA-detectable substance complex to produce an mRNA-peptide-detectable substance complex, and reverse transcribing an mRNA-peptide-detectable substance complex to obtain an mRNA-DNA-peptide-detectable substance complex. In one embodiment, the mRNA-DNA-peptide-detectable substance complex is detected by flow cytometry. In another embodiment, the mRNA-DNA-peptide-detectable substance complex is selected by FACS.

[0017] In one embodiment, the method of the invention comprises transcribing a template DNA library to obtain an mRNA library.

[0018] In one embodiment, the method of the present invention further comprises removing the mRNA-DNA-peptide complex that is not bound to the target. In one embodiment, the method of the present invention comprises removing the mRNA-DNA-peptide complex from the target.

[0019] In a specific embodiment, the mRNA-DNA-peptide complex is removed by adding acid or heating. In a specific embodiment, the mRNA-DNA-peptide complex is removed by heating. In one embodiment, the method further comprises amplifying the DNA of the removed mRNA-DNA-peptide complex by PCR. In one embodiment, the method further comprises transcribing the amplified DNA to obtain an mRNA library.

[0020] In one embodiment, the method of the invention comprises determining the amino acid sequence of the binding peptide. In one embodiment, the method of the invention further comprises determining the nucleic acid sequence of the binding peptide.

[0021] In one embodiment, the invention provides binding peptides detected or selected by the methods of the invention.

[0022] The present invention also provides mRNA-DNA-peptide complexes connected to at least one detectable substance. In one embodiment, the present invention provides a library of mRNA-DNA-peptide complexes connected to at least one detectable substance. In one embodiment, the detectable substance is a fluorophore. In one embodiment, the fluorophore is an organic dye, a biological fluorophore, or a quantum dot. In a specific embodiment, the detectable substance is Alexa Fluor. In one embodiment, the detectable substance is conjugated to a puromycin linker. In another embodiment, the detectable substance is a tag. In some such embodiments, the tag comprises a natural or unnatural amino acid. In one embodiment, the tag is a peptide tag. In some such embodiments, the tag is FLAG TM Tags. In one embodiment, the tag is detected by a fluorescent molecule. In a specific embodiment, the fluorescent molecule is a peptide or antibody linked to a fluorophore. DETAILED DESCRIPTION OF THE INVENTION

[0024] "Peptide" includes but is not limited to peptides, polypeptides, proteins, antibodies, antibody fragments and antibody fusion proteins. "Peptide" can be used interchangeably with polypeptides, proteins, antibodies, antibody fragments and antibody fusion proteins. As used herein, "binding peptide" refers to a peptide (including peptides, polypeptides, proteins, antibodies, antibody fragments and antibody fusion proteins) that binds to a target.

[0025] As used herein, "linker" refers to an agent that can be bound to a translation product. Linkers include, but are not limited to, amino acids, amino acid analogs, puromycin, and puromycin analogs. Preferably, the linker is an oligonucleotide fused to an aminonucleoside, such as puromycin or a puromycin analog, at its 3' end.

[0026] As used herein, "target" refers to a molecule that can interact with a translation product. The target can be a peptide, protein, nucleic acid (DNA or RNA), sugar, lipid, mammalian cell, mammalian cell extract, or other molecule with the ability to bind to a binding peptide. The target can be purified (including partial purification), inserted into the cell membrane, displayed on a phage, displayed on a yeast, displayed on a baculovirus, or displayed on a cell. The target can also be a protein expressed by a mammalian cell presented on a nanophospholipid disc (Nano discs), Amphipols, or liposomes. Nano discs and Amphipols are used to stabilize membrane-bound proteins.

[0027] A fluorophore attached (incorporated) to a DNA-linker, or a tag incorporated into an mRNA-DNA-peptide complex, are examples of "detectable substances" that are incorporated into the mRNA-DNA-peptide complex. "Attached" and "incorporated" (and their derivatives) are used interchangeably herein when referring to molecules or other such structures containing detectable substances.

[0028] Those skilled in the art will appreciate that FLAG TM The tag is given, for example, by the peptide sequence DYKDDDK. TM Tags, examples of other peptide tags that can be used in the methods of the present invention include, but are not limited to, HA-tag, His-tag, c-myc tag, and S-tag.

[0029] "Translation product" refers to the product of mRNA translation. Preferably, the translation product is a peptide that can bind to the target.

[0030] As used herein, "selection" and its derivatives refer to substantially isolating a molecule from other molecules in a library. After multiple rounds of selection, it is expected that molecules with a desired phenotype will be enriched in the library.

[0031] As used herein, "natural amino acids" refer to the 20 amino acids used in standard translation, which are α-amino carboxylic acids (or substituted amino carboxylic acids). This includes alanine (Ala), valine (Val), leucine (Leu), isoleucine (He), proline (Pro), tryptophan (Trp), phenylalanine (Phe), methionine (Met), glycine (Gly), serine (Ser), threonine (Thr), tyrosine (Tyr), cysteine ​​(Cys), glutamine (Gin), asparagine (Asn), lysine (Lys), arginine (Arg), histidine (His), aspartic acid (Asp) and glutamic acid (Glu).

[0032] As used herein, "non-natural amino acids" refer to amino acids that are generally different in structure from the 20 natural amino acids used in the natural translation process. Non-natural amino acids may include naturally occurring amino acids with modified functional groups. It includes all non-natural amino acids or artificial amino acids, including but not limited to D-amino acids, N-methyl amino acids, α-methyl amino acids, N-acyl amino acids, B (β)-amino acids, Y (γ)-amino acids and O (δ)-amino acids. δ amino acids are natural amino acids in which part of their side chain structure has undergone chemical changes / modifications, or derivatives having a structure in which the amino or carboxyl groups on the amino acid backbone are substituted. Peptides into which non-natural amino acids are introduced, or "non-natural peptides" as referred to herein, include polymers having these various non-natural amino acids as components. Non-natural peptides may be composed in part or in whole of non-natural amino acids. Therefore, non-natural peptides may have a main chain that is different in structure from a standard amide bond.

[0033] As used herein, "library" refers to a population of a plurality of molecules, such as a population of a plurality of nucleic acids, translation products, product / linker / mRNA complexes, and translation product / linker / mRNA-cDNA complex molecules. The diversity of a library can be expressed as different gene sequences. A DNA or RNA library refers to a DNA library or RNA library encoding a peptide library. Example

[0034] Example: Detecting the binding of mRNA-DNA-peptide complexes to targets

[0035] The peptide linked to its mRNA in the mRNA-DNA-peptide detectable complex (referred to herein as "peptide A") is used to determine whether flow cytometry can be used to detect the binding of the peptide to its target (referred to herein as "target A"). Target A can be a recombinant protein fused to an AVI tag (the tag is recombinantly fused to the target peptide to facilitate its site-specific biotinylation in vivo by biotin ligase (BirA)).

[0036] The messenger RNA encoding each peptide is annealed to a puromycin linker conjugated to a fluorophore (e.g., Alexa Fluor 647). Then, in vitro translation (IVT) is initiated using PDPS and the mRNA is reverse transcribed to produce an mRNA-DNA-peptide A complex. The mRNA-DNA-peptide A complex is added to the biotinylated target A-Avi tag for binding. Streptavidin-coated beads are added to the IVT mixture (containing the target A-Avi tag), and the streptavidin-coated beads are pulled down (pull-down) with the complex of biotinylated target A bound to the mRNA-DNA-peptide complex, washed and diluted in FACS buffer, followed by flow cytometry. Streptavidin beads are mixed with an in vitro transcription-translation mixture (IVT mixture) lacking amino acids and aminoacyl tRNA synthetase (ARS) [IVT(-)] and used as a negative control to ensure that the binding observed by flow cytometry is specific to the target A-Avi tag binding peptide.

[0037] Following the procedure essentially as described above in this example, it is expected that strong binding of the mRNA-DNA-peptide complex to its target (target A) will be detected.

[0038] Following the procedure essentially as described above in this Example, strong binding of the mRNA-DNA-peptide complex to its target (target A) was detected.

[0039] Example: Target-specific enrichment during mRNA library selection

[0040] To determine whether flow cytometry can be used to monitor selection by detecting the enrichment of target-specific peptides, selection rounds can be examined for the recombinant target A-Avi bound to streptavidin beads.

[0041] Chloroacetylphenylalanine is used to initiate translation and to form a stable thioether bond with the engineered cysteine ​​residue at the C-terminus. Selection was monitored by determining percent recovery by qPCR. Negative selection against streptavidin beads was incorporated in each round to eliminate nonspecific streptavidin binders. It is expected that the increase in percent recovery is most pronounced in later rounds, indicating enrichment of the identified target A binder population.

[0042] Then use Next generation sequencing was used to determine peptide sequences from later rounds. The high frequency of a few peptides could indicate enrichment of these specific peptides. To determine whether the observed increase in percent recovery could be due to the selection of nonspecific binders, peptide sequences from later rounds were compared to those from earlier rounds. It was expected that nonspecific binders would be enriched in later rounds using the qPCR approach. These nonspecific binders could include peptides with truncated sequences consisting of one or two amino acids.

[0043] Following essentially the procedure described above, the high frequency of a few peptides indicated the enrichment of these specific peptides. Comparison of peptide sequences from the later rounds with those from the earlier rounds revealed that these highly enriched peptides were truncated sequences consisting of one or two amino acids. In most cases, as the number of selection rounds increases, nonspecific binders will be enriched in later rounds. qPCR quantifies the number of DNA molecules indiscriminately, so true specific peptides cannot be distinguished from nonspecific peptides using this method. Therefore, methods other than qPCR should be used to improve the selection of specific binders.

[0044] To follow the enrichment of target A binding peptides from different selection rounds, flow cytometry was used. DNA from the output of different rounds was isolated and amplified by PCR to reconstitute each peptide pool with a fluorophore-conjugated puromycin linker, and each pool was evaluated for binding to target A-AVI by flow cytometry. Streptavidin plus IVT(-) samples were used for gating and as negative controls. Although the percentage recovery by qPCR is expected to increase, the increase in binding from different rounds by flow cytometry is expected to be small, if any. This may be due in part to reduced selection of non-specific binders recovered from flow cytometry.

[0045] Following essentially the procedure described above, the increase in percent recovery by qPCR indicated that later rounds should bind much more strongly to the target. However, no specific binding of the peptide pool to the target was observed by flow cytometry. The lack of binding of the peptide pool to the target by flow cytometry was confirmed by the enrichment of truncated nonspecific peptides in later rounds of selection.

[0046] Example: Isolation of target-specific binders from mRNA libraries using FACS

[0047] In order to determine whether the library screened for target A-AVI can be sorted by FACS, the puromycin linker fused to fluorophore (such as Alexa Flour 647) is used, the DNA output from the back round is transcribed and translated, and flow cytometry is performed to detect binding.Gating is around the target A-AVI compounded with streptavidin beads, and it is estimated that the peptide of low percentage will be combined with target A (library before sorting). Positive colony is sorted by flow cytometry, and the combination of peptide library and peptide A-AVI from the sorting round is assessed by flow cytometry. It is estimated that the result shows that compared with the library of pre-sorting, the combination of the sorting library significantly increases. It is estimated that the result also shows that compared with using traditional mRNA selection method, the selection carried out by FACS can cause more enrichment of target A binding peptides, and the selection carried out by FACS is an effective method to eliminate background binding substances and separate specific peptides.

[0048] Follow the program as described above basically, low percentage peptide is attached to target A (storehouse before sorting).Sorted this positive colony by flow cytometry, and assessed the combination of peptide storehouse and target A-AVI from this sorting round by flow cytometry.The result shows, compared with the storehouse before sorting, the combination of this sorting storehouse significantly increases.The result also shows, compared with using traditional percentage recovery method, the selection carried out by FACS has caused more enrichment of target A specific binding peptides, and the selection carried out by FACS is an effective method to eliminate background binding substances and separation specific peptides.

[0049] To further determine whether selection by percent recovery could result in enrichment of both specific and nonspecific binders, peptide sequences from the sorting rounds were compared to peptide sequences from the corresponding unsorted rounds. It is expected that several of the highest frequency sequences from the sorting rounds will be different from the unsorted rounds. In addition, the frequency of specific peptides is expected to increase after sorting by FACS. This suggests that selecting mRNA display libraries by FACS using a modified puromycin linker can efficiently isolate peptides with strong binding affinity and specificity.

[0050] Following essentially the procedure described above, several of the highest frequency sequence peptides from the sorting rounds were different from the unsorted rounds. After sorting by FACS, the frequency of specific peptides increased. This suggests that using a modified puromycin linker to select mRNA display libraries by FACS can efficiently isolate peptides with strong binding affinity and specificity.

[0051] Example: Detection and selection of cell-expressed peptides

[0052] The conventional mRNA display selection method cannot effectively detect the peptides expressed by cells because the inherent high noise of the system leads to the selection of non-specific peptides. Using PDPS for the recombinant heterodimeric protein expressed by cells (referred to herein as "protein P"; biotinylation; connecting streptavidin beads), four rounds of selection are completed. Streptavidin beads are used to pull down the complex of peptide and protein II, and the selection is monitored by determining the percentage recovery rate of each round. In the fourth round, a significant increase in the percentage recovery rate was observed (Table 1), so in part, by reducing the target concentration to facilitate the separation of stronger binders, the stringency of selection is increased.

[0053] Table 1. Percent recovery of recombinant protein II in each round of selection

[0054] Round % recovery for biotinylated protein II 1 0.0024 2 0.0072 3 0.27 4 2.92 5 0.057

[0055] In order to determine whether the protein expressed by the cell can be used as the target of the method of the present invention, flow cytometry is used to monitor the enrichment of protein II-binding objects during selection for recombinant or cell-expressed protein II. DNA from the second to fifth rounds of output is transcribed, annealed to the modified puromycin linker, and translated to constitute the fluorophore library of each round. The binding of each mRNA-DNA-peptide library to recombinant or cell-expressed protein II is detected by flow cytometry.

[0056] Following essentially the procedure described above, the outputs from rounds 2 to 5 produced strong binding to recombinant and cell-expressed protein II as detected by flow cytometry (Table 2). These data demonstrate that the methods of the invention can be used to select recombinant and cell-expressed peptides.

[0057] Table 2. Binding of mRNA-DNA-peptide libraries to Protein II from different selection rounds and detected by flow cytometry

[0058]

[0059] Then the DNA from the second round of output is used to sort protein II binders using FACS. Since recombinant forms of proteins were used in the first round of selection, protein II expressed on CHO cells was sorted to separate compounds that were all combined with both forms (recombinant or cell expressed) of the target. In order to determine whether the enrichment of protein II binders can be caused by FACS sorting, the binding of peptide pools to protein II before and after sorting was checked. The results show that, as determined by flow cytometry, the population enrichment of specific binders after sorting (4% binders before sorting and 40% binders after sorting) is minimal for the sorted library and the parent CHO cells lacking protein II expression. The next generation sequencing of the second round (sorted) peptides shows that new families have appeared, and their sequences are not present at detectable levels in pre-sorting and subsequent rounds of selection (carried out by conventional mRNA display selection methods).

[0060] To determine how the most enriched peptides in the second round (sorted) library compared to the fifth round of binding and functional activity, peptides identified from the second round (sorted) library were chemically synthesized and tested in a cell-based functional assay to determine whether the binding of protein II to its ligand can be blocked by the sorted peptides. It is expected that the data will demonstrate that the peptides present in the second round (sorted) library will inhibit the interaction of protein II with its ligand. These results will indicate that FACS sorting in earlier selection rounds can lead to the isolation and identification of functionally active peptides, and that these peptides may be depleted from the library in subsequent rounds due to multiple rounds of selection.

[0061] Following essentially the procedure described above, peptides present in the second round (sorted) pool inhibited the interaction of protein II with its ligand.

[0062] Example: Design and optimization of DNA-linkers conjugated to fluorophores

[0063] Fluorophore is conjugated (connected) to the 5' end of puromycin linker, thereby allowing the detection of mRNA-DNA-peptide complex by flow cytometry. Using NHS ester linker or spacer of different lengths, fluorophore can be directly conjugated to the 5' end of oligonucleotide. Connection can be carried out, for example, as follows: puromycin is covalently linked to the 3'-end of short oligonucleotide linker by multiple hexaethylene glycol spacers. It is believed that when multi-spanning membrane proteins (GPCR and ion channels) are targets, or when peptides are combined with the cavity or groove of proteins, increasing the length of the spacer is the most effective. For example, the combination of mRNA-DNA-peptide and multi-spanning cell-expressed protein (herein referred to as "protein III") complex expressed on the surface of HEK cells is better detected by flow cytometry as the length of the spacer increases (Table 3). This may be due to the increase in the accessibility of the fluorophore as the length of the linker increases. However, the data in Table 3 also show that the spacer may not be required for flow cytometry detection.

[0064] Table 3 Detection of binding of mRNA-DNA-Protein III complex using modified puromycin linker

[0065]

[0066] *HEK cells without exogenous receptors were used as negative control.

Claims

1. A method for detecting and selecting a binding peptide of a target, wherein the method comprises: a) incorporating at least one fluorophore into the RNA library via a puromycin linker conjugated to the fluorophore to generate an mRNA-fluorophore complex; b) translating the mRNA-fluorophore complex to produce an mRNA-peptide-fluorophore complex; c) reverse transcribing the mRNA-peptide-fluorophore complex to obtain the mRNA-DNA-peptide-fluorophore complex; d) detecting the mRNA-DNA-peptide-fluorophore complex by flow cytometry; and e) selecting the binding peptides by fluorescence activated cell sorting.

2. The method of claim 1, wherein the fluorophore is an organic dye, a biological fluorophore, or a quantum dot.

3. The method of claim 1, wherein the binding peptide comprises at least one unnatural amino acid.

4. The method of claim 1, wherein the method further comprises transcribing the template DNA library to obtain the mRNA library.

5. The method of claim 1, further comprising removing mRNA-DNA-peptide complexes that are not bound to the target.

6. The method of claim 1, further comprising removing the mRNA-DNA-peptide complex from the target.

7. The method of claim 6, wherein the mRNA-DNA-peptide complex is removed by heating.

8. The method of claim 6, further comprising amplifying the DNA in the removed mRNA-DNA-peptide complex by PCR.

9. The method of claim 8, further comprising transcribing the DNA to obtain an mRNA library.

10. The method of any one of claims 1-9, further comprising determining the amino acid sequence of the binding peptide.

11. The method of any one of claims 1-9, further comprising determining the nucleic acid sequence of the binding peptide.